Collaborations with other AFOSR-Funded Scientists-
(1) Dr. David Harris. We exposed numerous mice to JP-8 jet fuel for his immune system studies.
(2) Dr. Frank Witzmann. We are working closely with Dr. Witzmann to characterize various organ systems' proteomic response to JP-8 jet fuel.
(3) Dr. Vijayalaxmi. We are exposing mice to low levels of JP-8 jet fuel for DNA micronuclei studies.
(4) Dr. Mark Smulson. We are working with Dr. Smulson to characterize various organ system's genomic response to JP-8 jet fuel.
(5) Dr. Larry Fechter. We are exposing rats to various levels of JP-8 jet fuel exposure for hearing studies.
(6) Dr. Jeff Fisher. We are conducting pharmacokinetic studies for both aerosol and vapor JP-8 jet fuel exposure scenarios.
Manuscripts Published from 2000-2003 with Key Findings-
(1) Robledo RF, Young RS, Lantz RC, Witten ML: Short-term pulmonary response to inhaled JP-8 jet fuel aerosol in mice. TOXICOLOGIC PATHOLOGY, 2000, 28:656. We found that JP-8 jet fuel exposures as low as 50 mg/m^ caused pathological evidence of lung injury at the lung terminal bronchioles. A substance P analog, Sar9, Met (02) 11-substance P treatment in our acute diesel fuel smoke exposure model caused decreases in PGE2 and PGI2 in the lungs of rabbits, possibly demonstrating a protective effect for the substance P analog. The Sar9, Met (02) 11-substance P was administered by intravenous methods rather than aerosol delivery. This finding is important since the U.S. Food & Drug Administration wants us to develop a direct injection method for administration of Sar9, Met (02)11-substance P. We demonstrated that co-cultures of pulmonary alveolar macrophages and alveolar type II epithelial cells with JP-8 jet fuel exposure caused significant differences in lung cytokine production. We speculate that these data demonstrate "cross-talk" between pulmonary alveolar macrophages and alveolar type II epithelial cells. This "cell-to-cell" communication may be crucial for the lungs' defense against the damaging effects of JP-8 jet fuel exposure. We demonstrated vast differences in young mice's lungs' (6 weeks old) response to JP-8 jet fuel exposure -vs-one year old mice's lungs' response (equivalent to middle-aged humans). This research has vast implications for Air Force personnel who are exposed to continual JP-8 jet fuel exposure throughout their military careers.
(10) Hays AM, Lantz RC, Witten M: Correlation between in vivo and in vitro pulmonary responses to jet propulsion fuel-8 using precision-cut slices and a dynamic organ culture system. TOXICOLOGIC PATHOLOGY, 2003, 31:200. We have developed an in vitro lung cell culture system to investigate toxic effects of JP-8 jet fuel exposure and possibly utilize the two-photon confocal microscope system in a "real-time, in-line" JP-8 jet fuel exposure scenario in lung slices. (12) Drake M, Hyde J, Witzmann F, Witten ML: Lung proteomic profiles at two different JP-8 exposure levels. TOXICOLOGY, 2003,191:199. We investigated changes in lung proteins at low levels of JP-8 jet fuel exposure, 200 mg/m^ for one hour/day for seven days. We found that this exposure level in mice significantly reduced alpha-1-antitrypsin levels in the lungs. These findings may have very important implications for Air Force personnel since deficiency of alpha-1-antitrypsin in humans is known to contribute to the development of emphysema.
(13) Wong S, Hyde JD, Rowland S, Sun NN, Witten ML: Hong Kong respiratory virusinduced lung injury is potentiated by prior JP-8 jet fuel exposure. TOXICOLOGY (in press).
We have developed a JP-8 jet fuel-exposed influenza respiratory virus, A/Hong Kong/8/68 mouse-adapted virus, model that demonstrates that JP-8 jet fuel exposure prior to respiratory virus infection potentiates the severity of respiratory illness from the influenza virus. The mice were administered 10 microliters of the Hong Kong virus in their nasal passages. On Day +7 after viral inoculation, the JP-8 jet fuel + Hong Kong virus mice demonstrated obvious signs of illness by lethargy, dehydration, decreased body weight, and Acute Respiratory Distress Syndrome. Recently, we administered our substance P analog, Sar9, Met (02)11-substance P, after JP-8 jet fuel exposure followed by inoculation with the Hong Kong virus. We demonstrated that our substance P analog significantly decreased lung leukotriene B4 levels by three-fold as well as brought lung inflammatory cell levels to normal values. Additionally, on a pathological basis, treatment with our substance P analog preserved lung airway cilia as well as the airway epithelial cells had normal mitochondria levels. Furthermore, we did not observe any Hong Kong virus virons in the mice treated with our substance P analog, possibly indicating that pulmonary alveolar macrophages were activated to phagocytize the Hong Kong virus virons. These findings have important implications for Severe Acute Respiratory Syndrome (SARS) and Avian Flu outbreaks in Asia as well as Air Force personnel transferred to foreign areas for combat operations where they potentially could encounter SARS, Avian Flu, or other new types of respiratory viruses.
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Inventions/Patents/Discoveries
(1) Provisional patent by the University of Arizona concerning the development of a diagnostic test for acute leukemia patients to predict success of chemotherapy treatment.
(2) Provisional patents for SARS, hair replacement treatment, acute radiation syndrome, and respiratory viruses for our substance P analog, Sar9, Met (02)11-substance P drug compound.
Transitions/Technology Transfers-
We have formed ImmuneRegen Biosciences, Inc. and ImmuneRegen Biosciences-Asia with ImmuneRegen Biosciences, Inc. being a public company as of July 2, 2003. ImmuneRegen Biosciences-Asia was formed in early March 2004 in Singapore. The substance P patents developed under sponsorship of the Air Force Office of Scientific Research were transferred to ImmuneRegen Biosciences, Inc. and the company is pursuing a four-pronged strategy to bring the Sar9, Met (02) 11-substance P drug to market as quickly as possible for the benefit of mankind and for possible use in the War on Terrorism. The drug development process is for the following four applications-(1) Acute Respiratory Distress Syndrome including the SARS virus. We have signed a consulting agreement with Ever Progressing Systems of Singapore to begin clinical trials in Singapore for Acute Respiratory Distress Syndrome within the next six months.
(2) Attenuation of Cigarette-Smoke Induced Lung Injury. We have signed a consulting agreement with Ever Progressing Systems of Singapore to begin clinical trials in Singapore within the next 6-9 months.
(3) Acute Radiation Syndrome. We have demonstrated a 50% survival rate in mice administered a lethal dose of gamma radiation. We met with the U.S. Food & Drug Administration on March 12, 2004 in Rockville, Maryland. The Division of CounterTerrorism gave us a 10 page summary of our drug development at this point in time. Two key points were raised by the U.S. FDA and they are the following-(a) They want us to develop a direct injection method for the administration of Sar9, Met (02)11-substance P for possible use by the U.S. military against acute radiation exposure.
(b) They want us to develop a rapid-response team to administer the Sar9, Met (02)11-substance P drug anywhere in the world in response to terrorist attacks with "dirty radioactive bombs".
(4) Hair Replacement Treatment. The gamma radiation-exposed mice also were observed to retain their hair. This is a potential treatment for humans undergoing chemotherapy or radiation treatments for cancer. 
